temporarily placed on the EuroGentest (http://www.eurogentest.org/ professionals/documents/info/public/unit3/geneCards.xhtml), ESHG (http://www.eshg.org), and Orphanet (http://www.orpha.net) websites, inviting for general and specific commentaries from the scientific community. In a second step, presented in this journal, the guidelines have now been reedited and referenced by a number of European experts.
Although the clinical utility gene cards claim to represent the state of the art at the time of publication, the rapid medico-scientific progress in this field will require regular updates, a service that EuroGentest hopes to be able to provide in the years to come.
We hope that this activity will be found useful and incite expansion. This editorial is thus also intended to serve as a call to the genetics community to collaborate on further submissions of clinical utility gene cards for diseases not yet covered (http://www.orpha.net).
